Jessica Fye

Mayank Mamtani

Yasmeen Rahimi

Arthur He

Jay Olson

Alexandra Ramsey

Andy Hsieh

Cha Cha Yang

Cheng Li

Dominic Risso-Gill

Eric Joseph

Jiale Song

Roger Song

Tsan-Yu Hsieh

Yu He

Yu He (Arthur)

- Nektar Therapeutics reported **positive new data** from its **REZOLVE-AD Phase 2b study** of rezpegaldesleukin for moderate-to-severe atopic dermatitis on **September 18, 2025**.  **[906709_0001213900-25-088792_ea025784201ex99-2_nektar.htm:0]** 
- The study **met its primary and key secondary endpoints at week 16**, with all rezpegaldesleukin arms showing statistically significant mean improvement in Eczema Area and Severity Index (EASI) compared to placebo.  **[906709_0001213900-25-088792_ea025784201ex99-2_nektar.htm:0]** 
- Interim data for patients who crossed over from placebo to high-dose rezpegaldesleukin demonstrated a deepening of clinical effect, with **EASI-75 response reaching 62%** and **vIGA-AD 0/1 response reaching 38%** after 24 weeks of treatment.  **[906709_0001213900-25-088792_ea025784201ex99-2_nektar.htm:0]** 
- The safety profile was consistent with previous data, showing no new safety concerns, and **Phase 3 planning for moderate-to-severe atopic dermatitis is currently underway**.  **[906709_0001213900-25-088792_ea025784201ex99-1_nektar.htm:6]**

Nektar Therapeutics Announces Positive Phase 2b REZOLVE-AD Study Results for Rezpegaldesleukin

- Nektar Therapeutics announced **positive new data** from its REZOLVE-AD Phase 2b study of **rezpegaldesleukin** for moderate-to-severe atopic dermatitis at the 2025 European Academy of Dermatology and Venereology (EADV) Congress.  **[906709_20250918SF76843:0]** 
- The study met its **primary and key secondary endpoints** at week 16, with all rezpegaldesleukin arms achieving statistical significance over placebo.  **[906709_20250918SF76843:0]** 
- Interim data for patients who crossed over from placebo to high-dose rezpegaldesleukin showed a **deepening of clinical effect**, with EASI-75 response reaching **62%** and vIGA-AD 0/1 response reaching **38%** after 24 weeks of treatment.  **[906709_20250918SF76843:0]** 
- Rezpegaldesleukin has received **Fast Track designation** from the U.S. Food and Drug Administration (FDA) for moderate-to-severe atopic dermatitis (February 2025) and severe alopecia areata (July 2025).  **[906709_20250918SF76843:2]**

Nektar Therapeutics Presents Positive Phase 2b REZOLVE-AD Study Data

- Nektar Therapeutics' ResPEG, a regulatory T cell inducer, demonstrated **dose-dependent efficacy** and **profound disease control** for up to **six months after treatment cessation** in a Phase 1b study for atopic dermatitis, with these findings replicated and extended in a larger Phase 2b study involving **393 patients**.  **[906709_2144681_0]** **[906709_2144681_1]** 
- ResPEG is designed as a **full agonist of the IL-2 receptor** for durable signaling, aiming to differentiate from current IL-4/IL-13 class treatments by offering **prolonged periods of disease control** and potential for remission, unlike existing drugs that require continuous dosing.  **[906709_2144681_1]** **[906709_2144681_2]** 
- In the Phase 2b study, **injection site reactions (ISRs)** were the most frequent adverse event, occurring in approximately **70% of patients**, but were primarily **local, transient, mild to moderate (99.6%)**, and rarely led to discontinuation (**0.6%**).  **[906709_2144681_3]** 
- Key upcoming catalysts include the presentation of **patient-reported outcomes and extended duration dosing data** from the atopic dermatitis Phase 2b study later this week (as of 2025-09-15), **full 2B maintenance data in Q1 2026**, and **topline data from the Phase 2 alopecia areata study in December 2025**.  **[906709_2144681_3]** **[906709_2144681_4]**

Nektar Therapeutics Reports Positive Phase 2b Atopic Dermatitis Data for ResPEG and Outlines Upcoming Catalysts

NEKTAR THERAPEUTICS (NKTR)